[
  {
    "ts": "2025-12-09T15:00:00+00:00",
    "headline": "Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
    "summary": "SAN FRANCISCO, December 09, 2025--Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
    "url": "https://finance.yahoo.com/news/biotech-showcase-2026-returns-san-150000392.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "9a7bc750-929d-302b-93d3-7140f24876cc",
      "content": {
        "id": "9a7bc750-929d-302b-93d3-7140f24876cc",
        "contentType": "STORY",
        "title": "Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
        "description": "",
        "summary": "SAN FRANCISCO, December 09, 2025--Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
        "pubDate": "2025-12-09T15:00:00Z",
        "displayTime": "2025-12-09T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/819070b87814e5b570afa950053390c3",
          "originalWidth": 480,
          "originalHeight": 275,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FLB.fS2TdtItQke6IDYB0Q--~B/aD0yNzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/819070b87814e5b570afa950053390c3.cf.webp",
              "width": 480,
              "height": 275,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q8KKFmqH9yra4q8gkEB58w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/819070b87814e5b570afa950053390c3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biotech-showcase-2026-returns-san-150000392.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biotech-showcase-2026-returns-san-150000392.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IPSEF"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T16:39:20+00:00",
    "headline": "​Sanofi (SNY) Completes the Acquisition of Vicebio",
    "summary": "​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus […]",
    "url": "https://finance.yahoo.com/news/sanofi-sny-completes-acquisition-vicebio-163920258.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "66d33592-47ed-3b40-8e16-5302c792312c",
      "content": {
        "id": "66d33592-47ed-3b40-8e16-5302c792312c",
        "contentType": "STORY",
        "title": "​Sanofi (SNY) Completes the Acquisition of Vicebio",
        "description": "",
        "summary": "​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus […]",
        "pubDate": "2025-12-09T16:39:20Z",
        "displayTime": "2025-12-09T16:39:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4f7369a8cd76489e18c06afee0976ddc",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OiLNv3YhiGdV9J6vk1l75Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4f7369a8cd76489e18c06afee0976ddc.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZlW0Wpx0Vz0_itMp4u_YGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4f7369a8cd76489e18c06afee0976ddc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sanofi-sny-completes-acquisition-vicebio-163920258.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sanofi-sny-completes-acquisition-vicebio-163920258.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T16:50:00+00:00",
    "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
    "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
    "url": "https://www.barrons.com/articles/pfizer-licenses-china-weight-loss-drug-congress-biotechs-5da94738?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "79109b8c-1cf7-365e-ac9e-dd9479092fa2",
      "content": {
        "id": "79109b8c-1cf7-365e-ac9e-dd9479092fa2",
        "contentType": "STORY",
        "title": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
        "description": "",
        "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
        "pubDate": "2025-12-09T16:50:00Z",
        "displayTime": "2025-12-09T16:50:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/79109b8c-1cf7-365e-ac9e-dd9479092fa2/pfizer-turns-to-china-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/26054c514293e05d6564954cf6bcd168",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bpUZmpLX9FPaGDk0jzM_nA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/26054c514293e05d6564954cf6bcd168.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NYQgESOFFGFpUk4exawZZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/26054c514293e05d6564954cf6bcd168.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/pfizer-licenses-china-weight-loss-drug-congress-biotechs-5da94738?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]